Annual report
4521.TEDINET S100R4OM
Period2022-04-01 → 2023-03-31
Filed2023-06-29
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥73.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥76.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥75.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥89.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥94.2bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥8.0bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥17.1bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥8.7bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥17.5bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥18.2bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥26.9bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥25.0bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥6.8bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥13.9bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥9.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.4bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥19.4bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥17.8bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥5.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥9.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥166.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥165.2bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥163.3bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥157.9bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥156.0bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥29.5bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥26.9bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥136.8bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥138.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥136.3bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥128.5bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥121.1bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥59.6bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥61.0bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥74.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥74.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥77.3bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥73.3bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥58.6bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥9.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥13.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥14.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥27.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥21.1bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥7.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥5.7bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥7.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥8.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥8.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥10.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥9.5bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥144.8 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥251.43 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥347.37 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥494.89 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥445.78 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥3,636.17 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,642.34 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,555.93 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,301.09 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,049.78 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 81.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.4% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.4% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.4% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.7% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 4.0% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.0% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.1% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 15.5% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 15.1% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,130 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 1,164 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 1,215 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 1,268 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 1,341 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥72.9bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥75.9bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥73.9bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥87.6bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥92.5bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥8.4bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥17.4bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥8.9bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥17.9bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥18.2bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥26.9bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥24.9bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥8.6bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥14.2bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥6.8bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥9.9bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥13.4bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥19.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥17.7bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥163.7bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥161.8bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥162.3bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥156.3bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥154.3bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥27.2bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥25.2bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥136.6bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥136.6bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥135.0bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥128.7bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥120.9bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥58.3bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥59.6bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥180.07 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥260.61 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥346.63 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥493.31 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥443.8 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥150 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥150 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥150 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥150 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥150 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥3,644.33 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,611.75 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,521.92 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,306.96 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,045.17 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 83.4% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.4% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.1% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 82.4% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.4% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 5.0% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.1% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.5% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.1% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 45,939,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 45,939,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 45,939,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 45,939,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 48,439,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 1,117 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 1,152 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 1,207 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 1,258 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 1,333 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 42
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥82.0bn |
| Medicinereportable segment | capex | 2022-04-01 → 2023-03-31 | ¥2.8bn |
| Medicinereportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥2.7bn |
| Medicinereportable segment | employees | at 2023-03-31 | 1129 pure |
| Medicinereportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥70.6bn |
| Medicinereportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥70.6bn |
| Medicinereportable segment | segment assets | at 2023-03-31 | ¥74.2bn |
| Medicinereportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥6.7bn |
| Real Estatereportable segment | capex | 2022-04-01 → 2023-03-31 | ¥19m |
| Real Estatereportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥322m |
| Real Estatereportable segment | employees | at 2023-03-31 | 1 pure |
| Real Estatereportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥2.4bn |
| Real Estatereportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥2.4bn |
| Real Estatereportable segment | segment assets | at 2023-03-31 | ¥10.1bn |
| Real Estatereportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.3bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥2.8bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥3.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥73.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥73.0bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥84.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥8.0bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥79.2bn |
| Medicinereportable segment | capex | 2021-04-01 → 2022-03-31 | ¥11.3bn |
| Medicinereportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥2.7bn |
| Medicinereportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥73.6bn |
| Medicinereportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥73.6bn |
| Medicinereportable segment | segment assets | at 2022-03-31 | ¥75.6bn |
| Medicinereportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥15.7bn |
| Real Estatereportable segment | capex | 2021-04-01 → 2022-03-31 | ¥508m |
| Real Estatereportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥322m |
| Real Estatereportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥2.4bn |
| Real Estatereportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥2.4bn |
| Real Estatereportable segment | segment assets | at 2022-03-31 | ¥10.4bn |
| Real Estatereportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥11.9bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥3.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥76.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥76.0bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥86.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥17.1bn |
| Medicinereportable segment | employees | at 2023-03-31 | 1116 pure |
| Real Estatereportable segment | employees | at 2023-03-31 | 1 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,718
| Item | Context | Value | Unit |
|---|---|---|---|
| Amortization of goodwill sga | Prior1YearDuration_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | 5000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | － | JPY |
| Amortization of goodwill sga | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 5000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Amortization of goodwill sga | Prior1YearDuration | 5000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | 11347000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | 508000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 11856000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration | 11856000000 | JPY |
| Net sales of finished goods and merchandise | CurrentYearDuration_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | 68785000000 | JPY |
| Net sales of finished goods and merchandise | CurrentYearDuration_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | － | JPY |
| Net sales of finished goods and merchandise | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 68785000000 | JPY |
| Net sales of finished goods and merchandise | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Net sales of finished goods and merchandise | CurrentYearDuration | 68785000000 | JPY |
| Royalty | CurrentYearDuration_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | 1776000000 | JPY |
| Royalty | CurrentYearDuration_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | － | JPY |
| Royalty | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 1776000000 | JPY |
| Royalty | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Royalty | CurrentYearDuration | 1776000000 | JPY |
| Other income | CurrentYearDuration_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | － | JPY |
| Other income | CurrentYearDuration_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | 2422000000 | JPY |
| Other income | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 2422000000 | JPY |
| Other income | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Other income | CurrentYearDuration | 2422000000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | 70562000000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | 2422000000 | JPY |
| Revenues from external customers | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 72984000000 | JPY |
| Revenues from external customers | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYearDuration | 72984000000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYearDuration | － | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | 70562000000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | 2422000000 | JPY |
| Net sales | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 72984000000 | JPY |
| Net sales | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Net sales | CurrentYearDuration | 72984000000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | 6707000000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | 1290000000 | JPY |
| Operating income | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 7998000000 | JPY |
| Operating income | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Operating income | CurrentYearDuration | 7998000000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | 74223000000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | 10090000000 | JPY |
| Assets | CurrentYearInstant_TotalOfReportableSegmentsAndOthersMember | 84314000000 | JPY |
| Assets | CurrentYearInstant_ReconcilingItemsMember | 82013000000 | JPY |
| Assets | CurrentYearInstant | 166328000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |